Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab or placebo plus nab-paclitaxel for newly diagnosed stage IV or recurrent/metastatic triple-negative breast cancer
CTR20191428Phase 3Completed
- Sponsor
- Junshi Biosciences
- Start
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in triple-negative breast cancer (TNBC), sponsored by Junshi Biosciences. Started Dec 2018; status: completed.
02
Drugs
toripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20191428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191428.